MedTrace Logo

A Study of RO7890597 in Healthy Adult Volunteers

NCT07797478 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2026-09-01

No results posted yet for this study

Summary

This study will evaluate the safety, pharmacokinetics (PK), and activity of single and multiple doses of RO7890597 compared with placebo in healthy volunteers. The study includes single ascending dose (SAD) stage, multiple ascending dose (MAD) stage, food-effect and proton pump inhibitor (PPI) stages, and a supplemental drug-drug interaction (DDI) stage.

Conditions

  • Healthy Volunteers

Interventions

DRUG

RO7890597

Participants will receive RO7890597 as per the schedule described in the protocol.

DRUG

Placebo

Participants will receive matching placebo as per the schedule described in the protocol.

DRUG

Rabeprazole

Participants will receive rabeprazole as per the schedule described in the protocol.

DRUG

Itraconazole

Participants will receive itraconazole as per the schedule described in the protocol.

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Genentech, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-28
Primary Completion
2027-06-08
Completion
2027-06-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07797478 on ClinicalTrials.gov